Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 24:52:100682.
doi: 10.1016/j.jbo.2025.100682. eCollection 2025 Jun.

Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies

Affiliations
Review

Artificial Intelligence in bone Metastases: A systematic review in guideline adherence of 92 studies

Lotte R van der Linden et al. J Bone Oncol. .

Abstract

Background: The last decade has witnessed a surge in artificial intelligence (AI). With bone metastases becoming more prevalent, there is an increasing call for personalized treatment options, a domain where AI can greatly contribute. However, integrating AI into clinical settings has proven to be difficult. Therefore, we aimed to provide an overview of AI modalities for treating bone metastases and recommend implementation-worthy models based on TRIPOD, CLAIM, and UPM scores.

Methods: This systematic review included 92 studies on AI models in bone metastases between 2008 and 2024. Using three assessment tools we provided a reliable foundation for recommending AI modalities fit for clinical use (TRIPOD or CLAIM ≥ 70 % and UPM score ≥ 10).

Results: Most models focused on survival prediction (44/92;48%), followed by imaging studies (37/92;40%). Median TRIPOD completeness was 70% (IQR 64-81%), CLAIM completeness was 57% (IQR 48-67%), and UPM score was 7 (IQR 5-9). In total, 10% (9/92) AI modalities were deemed fit for clinical use.

Conclusion: Transparent reporting, utilizing the aforementioned three evaluation tools, is essential for effectively integrating AI models into clinical practice, as currently, only 10% of AI models for bone metastases are deemed fit for clinical use. Such transparency ensures that both patients and clinicians can benefit from clinically useful AI models, potentially enhancing AI-driven personalized cancer treatment.

Keywords: Artificial Intelligence; Guidelines; Machine Learning; Metastatic bone disease; Systematic Review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
PRISMA flowchart of study inclusions and exclusions * The search was conducted on February 29th 2024.
Fig. 2
Fig. 2
Overview of growing amount of studies published on AI in bone metastases.
Fig. 3
Fig. 3
Overview of used AI techniques in all 92 models. * Other refers to: Elastic Net Penalized Logistic Regression (48%; 16/33), Logistic Regression (15%; 5/33), Lasso Regularization Logistic Regression (6%; 2/33), Computer aided detection (3%; 1/33), OG-Domain Diffeomorphic Demons Algorithm (3%; 1/33), Multi View-Attention-Guided Network (3% 1/33), Bayes Point Machine (3%; 1/33), Naive Bayes (3%; 1/33), Ensemble Prediction (3%; 1/33), Masked Thresholding (3%; 1/33), Radiomics (3%; 1/33), CatBoost Classifier (3%; 1/33), and Bayesian Classifier (3%; 1/33).

Similar articles

References

    1. Anderson A.B., Wedin R., Fabbri N., Boland P., Healey J., Forsberg J.A. External Validation of PATHFx Version 3.0 in Patients Treated Surgically and Nonsurgically for Symptomatic Skeletal Metastases. Clin Orthop Relat Res 478. 2020:808–818. doi: 10.1097/CORR.0000000000001081. - DOI - PMC - PubMed
    1. de Groot T.M., Ramsey D., Groot O.Q., Fourman M., Karhade A.V., Twining P.K., Berner E.A., Fenn B.P., Collins A.K., Raskin K., Lozano S., Newman E., Ferrone M., Doornberg J.N., Schwab J.H. Does the SORG Machine-learning Algorithm for Extremity Metastases Generalize to a Contemporary Cohort of Patients? Temporal Validation From 2016 to 2020. Clin Orthop Relat Res. 2023 doi: 10.1097/CORR.0000000000002698. - DOI - PMC - PubMed
    1. Karhade A.V., Groot O., Shah A.A., Bilsky M.H., Laufer I., Park D.Y., Sciubba D.M., Tobert D.G., Bono C.M., Schwab J.H. 61. Development and external validation of predictive algorithms for six-week mortality in spinal metastasis using 4304 patients from five institutions. Spine Journal. 2022;22:S32. doi: 10.1016/j.spinee.2022.06.075. - DOI - PubMed
    1. Karhade A.V., Thio Q.C.B.S., Ogink P.T., Bono C.M., Ferrone M.L., Oh K.S., Saylor P.J., Schoenfeld A.J., Shin J.H., Harris M.B., Schwab J.H. Predicting 90-Day and 1-Year Mortality in Spinal Metastatic Disease: Development and Internal Validation. Neurosurgery. 2019;85:E671–E681. doi: 10.1093/neuros/nyz070. - DOI - PubMed
    1. DiCaprio M.R., Murtaza H., Palmer B., Evangelist M. Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease. Ann Joint. 2022;7:28. doi: 10.21037/aoj-20-97. - DOI - PMC - PubMed

LinkOut - more resources